Skip to main content
ENTA logo

ENTA · Enanta Pharmaceuticals Inc · Metrics

Track ENTA — free
$12.96 +0.26 (+2.05%) At close · Sep 11
Market Cap
$377.47M
Shares
29.13M

ENTA metrics

63 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.96
Market cap
$377.47M

Price action

20 metrics
Price change (1W)
-8.0%
Price change (30D)
-3.6%
Price change (3M)
+8.9%
Price change (6M)
+2.0%
Price change (YTD)
-17.8%
Price change (1Y)
+49.7%
Trailing year
Price change (5Y)
-76.9%
52-week high
$16.85
52-week low
$7.17
Change from 52-week high
-23.1%
Change from 52-week low
+80.8%
Annualized volatility
107.6%
Annualized volatility (3M)
44.5%
Beta
1.0
RSI (14D)
43.4
Price vs SMA 50
-3.8%
Price vs SMA 200
-4.9%
Avg volume (3M)
219,740
Relative volume
1.3
Average dollar volume
$2.98M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
29.13M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
5.8×
reciprocal yield 17.3%
P / book
3.7
reciprocal yield 26.8%
FCF yield
-9.8%
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-16.8%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2024-11-25

Profitability

9 metrics
Gross margin
Operating margin
-90.0%
Trailing 12 months
Net margin
-96.9%
Gross profit (TTM)
Operating profit (TTM)
−$58.73M
Net income (TTM)
−$63.23M
Trailing 12 months
Diluted EPS (TTM)
$-2.42
FCF margin
-56.6%
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$3.03

Growth

11 metrics
Revenue growth YoY
-21.6%
Year over year
Net income growth YoY
Revenue (TTM)
$65.26M
Trailing 12 months
EPS growth YoY
Shares change YoY
+36.1%
Year over year · more shares
Revenue CAGR (3Y)
-8.8%
Revenue CAGR (5Y)
-11.8%
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-62.6%
Return on assets
-21.3%
Debt / equity
Current ratio
3.8
EBITDA (TTM)
−$53.82M
Free cash flow (TTM)
−$36.94M
Quick ratio
3.8
Interest coverage
-4.5
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Cash & equivalents
$33.42M
Total assets
$296.87M
Total debt

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$35.32M
Capital expenditures (TTM)
$1.62M
R&D (TTM)
$86.24M
SG&A (TTM)
Stock compensation (TTM)
$15.28M
R&D / revenue
132.1%
Stock compensation / revenue
23.4%

Ownership (13F)

3 metrics
13F filers
122
13F filer change QoQ
-11
Institutional ownership
93.8%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 10.2 days to cover
Days to cover
10.2d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
Insider-sentiment score

Risk flags

1 metrics
Going concern
Key facts CIK 1177648 CUSIP 29251M106 13F (30d) 40 filings 40 filers Visit website Investor relations